NT-proBNP Fast Test Kit

 (Immunofluorescence Assay)

Intended Use

NT-proBNP Fast Test Kit (Immunofluorescence Assay) is intended for in vitro quantitative determination of N-terminal B-type natriuretic peptide precursor (NT-proBNP) in human serum, plasma or whole blood samples. This test is used as an aid in the clinical diagnosis, prognosis and evaluation of Heart Failure (HF).

About NT-proBNP

N-terminal B-type natriuretic peptide precursor (NT-proBNP) is secreted from the left cardiac ventricle in response to volume and pressure overload. It's an inactive N-terminal fragment that split from BNP prohormone. NT-proBNP can be used to evaluate heart contractile, diastolic dysfunction, and ventricular segmental wall motion coordination. Besides, it has high sensitivity and negative predictive value (>97%).

Contents

1. For Getein1100

Package specifications: 25 tests/box, 10 tests/box

1) NT-proBNP test card in a sealed pouch with desiccant

2) Disposable pipet

3) User manual: 1 piece/box

4) SD card: 1 piece/box

5) Whole blood buffer: 1 bottle/box

2. For Getein1180

Package specifications: 25 tests/box, 10 tests/box

1) Getein NT-proBNP test card in a sealed pouch with desiccant

2) Disposable pipet

3) Sample diluent

4) User manual:1 piece/box

5) SD card: 1 piece/box

3. For Getein1600

Package specifications: 2×24 tests/kit, 2×48 tests/kit

1) Sealed cartridge with 24/48 Getein NT-proBNP test cards

2) User manual: 1 piece/box

Materials required for Getein1600:

1) Sample diluent: 1 bottle/box

2) Box with pipette tips: 96 tips/box

3) Mixing plate: 1 piece/box

Note: Components from different batches must not be interchanged.

Specifications

Applicable Device

Getein1100 Immunofluorescence Quantitative Analyzer

Getein1180 Immunofluorescence Quantitative Analyzer

Getein1600 Immunofluorescence Quantitative Analyzer

Clinical Application

1.    As a gold standard for the diagnosis and prognosis of heart failure.

2.    As an aid in the early detection for patients with heart failure;

3.    As an aid in the diagnosisand risk stratification of heart failure;

4.    As an aid in the distinguishing dyspnea caused by heart failure from other diseases;

5.    As an aid in themonitoring and prognostic assessment of heart failure treatment;

6.    As an aid in the risk stratification for ACS.